Positron emission tomography: current status and future challenges.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG) Positron Emission Tomography (PET) has become indispensable in clinical oncology.
• Evidence supporting PET's utility has grown substantially, including data from the Australian PET Data Collection Project.
• Hybrid PET-computed tomography (PET-CT) systems have largely superseded standalone PET since 2001, enhancing diagnostic capabilities.

Purpose of the Study:

• To provide a concise update on the current applications of FDG-PET in oncology.
• To highlight the diagnostic and therapeutic monitoring roles of FDG-PET.
• To review advancements in PET imaging technology, particularly PET-CT.

Main Methods:

• Review of current scientific and clinical evidence on FDG-PET in oncology.
• Analysis of the impact of hybrid PET-CT imaging.
• Focus on oncologic applications based on recent data.

Main Results:

• FDG-PET plays a vital role in diagnosing, staging, and restaging malignancies.
• PET imaging is effective in monitoring patient response to cancer therapies.
• Hybrid PET-CT offers improved diagnostic accuracy compared to PET alone.

Conclusions:

• FDG-PET remains a cornerstone in modern oncologic practice.
• The integration of PET with CT has significantly advanced cancer imaging.
• Continued research and data collection are essential for optimizing FDG-PET utilization in cancer care.